ABSTRACT
PAI-1 is a M r ~50,000 glycoprotein, which is the primary physiological inhibitor of the two plasminogen activators uPA and tPA. PAI-1 belongs to the serpin protein family. Studies of PAI-1 have contributed significantly to the elucidation of the protease inhibitory mechanism of serpins, which is based on a metastable native state becoming stabilised by insertion of the RCL into the central beta-sheet A and formation of covalent complexes with target proteases. In PAI-1, this insertion can occur in the absence of the protease, resulting in generation of a socalled latent, inactive form of the protein. PAI-1, in its active state, also binds to the extracellular protein vitronectin. When in complex with its target proteases, it binds with high affinity to endocytosis receptors of the low density receptor family.
INTRODUCTION
Plasminogen activator inhibitor-1 (PAI-1) is a fast and specific inhibitor of the serine proteases urokinasetype (uPA) and tissue-type (tPA) plasminogen activator, the second order rate constants for the inhibition reaction being between 10 6 and 10 7 M -1 s -1
. It is therefore the primary inhibitor of generation of the active, broad-spectrum serine protease plasmin from the zymogen plasminogen, and thus a main regulator of fibrin degradation and turnover of the extracellular matrix. PAI-1 belongs to the serpin family. Xray crystal structure analyses have shown that serpins, including PAI-1, are globular proteins containing 3 betasheets and 9 alpha-helices. They have an exposed peptide loop, the reactive center loop (RCL), which is of decisive importance for the inhibitory mechanism (for reviews, see [1] [2] [3] [4] . The general inhibitory mechanism of serpins has been Abbreviations: 1 single-chain tPA, 2 two-chain tPA elucidated in work published since the mid 80´s (for reviews, see 5-7), beginning with the first X-ray crystal structure of a serpin (8). Important contributions to the now generally accepted ideas about serpin inhibitory mechanisms were made from studies of PAI-1. In addition, PAI-1 has a number of unusual and unique properties of special interest for the understanding of the biochemical properties of serpins, including its ability to assume the latent conformation, to bind to the extracellular protein vitronectin, and to be endocytosed upon complex formation with uPA or tPA. We will here review some of the biochemical properties of PAI-1, seen in relation to general serpinology. This review is not meant to be a comprehensive one. Rather, we will emphasise aspects which have not been well covered in other reviews. Also, the reader is referred to other recent reviews for coverage of the physiological and pathophysiological functions of PAI-1 (9-12).
GENERAL BIOCHEMISTRY OF PAI-1
Functional evidence for the existence of the fibrinolytic inhibitor later to be known as PAI-1 was published in the late 70´s (13, 14) . Early on, PAI-1 was also called the fast acting inhibitor, the endothelial cell inhibitor and the beta-migrating endothelial inhibitor. Human PAI-1 protein was first purified to apparent homogeneity in 1984 (15) . Monoclonal antibodies against human PAI-1 became available in 1986 (16, 17) . cDNA for human PAI-1 was cloned by 4 groups in 1986 ( Figure 1 ) (18) (19) (20) (21) . The amino acid sequence of PAI-1 is now known in numerous mammalian species but in contrast, very little is known about the protein in non-mammalian species. In fact, an experimentally verified full-length mRNA or protein sequence has yet to be reported in any non-mammalian species although predicted protein sequences in the databases indicate that PAI-1 is also present in nonmammalian vertebrate species, including the phylogenetically relatively distantly related teleosts (e.g. zebrafish (Danio rerio) GenBank XP_684545). In pufferfish (Fugu rubripes), 26 proteins involved in clotting and fibrinolysis were searched against predicted protein sequences based on the full genome and although 21 orthologs were found, PAI-1 was one of the proteins that did not survive the backsearch as a true homologue in this study (22) . Interestingly, no convincing homologue was found for any of the 26 genes in the urochordate, the sea squirt (Ciona intestinalis) genome, thereby strongly suggesting that the main lines of the vertebrate clotting pathway evolved in the interval between the last common ancestor of the two (22) .
In higher primates, including humans and orangutans and old-world monkeys such as African green monkey, the PAI-1 gene gives rise to two different mature mRNA transcripts of 2.6 and 3.6 kb, respectively, due to the presence of two alternative polyadenylation sites in these species (23) . The two transcripts result in translation into the same protein sequence. However, new-world monkeys, such as owl monkey, bushbaby and lemur only contain the larger transcript (3.6 kb) as do more distantly related mammalian species including mouse, rat and cow, thus providing evidence that the mutation(s) giving rise to the additional shorter 2.6 kb transcript appeared 20-65 million years ago in the time between the divergence of the new-world monkeys and the old-world monkeys from the evolutionary line that leads to higher primates and humans (23) .
Phylogenetically, PAI-1 (SERPINE1) is most closely related to protease nexin-1 (PN-1; SERPINE2) and myxoma virus SERP-1 (SERPIN SPI-1) (4). Several serpins, such as PAI-2 (SERPINB2; also known as the placental inhibitor), PAI-3 (SERPINA5; also known as activated protein C inhibitor), PN-1 and neuroserpin (SERPINI1) can inhibit uPA and tPA in vitro but generally not as fast as PAI-1 (see Table 1 ).
Human PAI-1 has either 379 or 381 amino acids, which is caused by the presence of two possible cleavage sites for the signal peptidase in the N-terminus of the nascent protein (Figure 1 ). The signal peptide has either 23 or 21 amino acids, respectively. In purified preparations of PAI-1 from natural sources, each isoform constitutes about 50% (18, 24) . After cleavage, the amino acid sequence from the N-terminus is either VHHPP-or SAVHHPP-. The correct numbering of the amino acids is then S1-A2-etc, but most workers in the field have chosen the numbering V1-H2-etc. In this review the S1-A2-etc.-numbering will be used (18) with the serpin consensus alpha1-proteinase inhibitor (alpha1-PI) numbering in parenthesis (1) . A peculiar, but technically useful property of human PAI-1 is the lack of cysteines, which enables experimental insertion of cysteines into the PAI-1 structure for labelling with fluorescent probes. Mammalian PAI-1 has 3 potential sites for N-linked glycosylation, N211(228a), N267(278), and N331(341), and the glycosylation sites are conserved in all mammalian species. Although the predicted nonmammalian PAI-1 mRNA and protein sequences in the databases remain to be experimentally confirmed, an alignment between mammalian PAI-1 and the corresponding best hit in zebrafish (GenBank XP_684545), and thereby a putative teleost fish PAI-1 homologue, shows conservation of N211(228a) but substitutions of N267(278) and N331(341) by G and T, respectively, thus providing preliminary evidence that the mammalian PAI-1 glycosylation sites may not be conserved across vertebrate species. The actual glycosylation pattern has been analysed in PAI-1 naturally expressed by the human cell line HT-1080 or recombinantly expressed by the human cell line HEK293. Only the sites at N211(228a) and N267(278) are utilised, carrying glycans of a high mannose type and a biantennary complex type, respectively (25) . A reported crystal structure of glycosylated PAI-1 confirms the Figure 1 . Intron-exon structure of human plasminogen activator inhibitor 1 (PAI-1) gene with the protein sequence indicated below the nucleotide sequence. Protein secondary structure elements are based on pdb file 1LJ5 and are indicated by underlinings. Black/white highlighting indicates alternate exons. Red highlighting indicates amino acids encoded across a splice junction. The two alternative signal peptidase cleavage sites are indicated by black arrows above the sequence.
existence of glycans at position 211(228a) and 267(278) but only a small part of the glycan moieties is visible suggesting pronounced flexibility (26) . Recent data suggest, however, that the bi-antennary glycan complex at position 267(278) covers a hydrophobic cleft in the PAI-1 structure, exposed upon detachment of beta-strand 1C from beta-sheet during the process of PAI-1 latency transition (27) (see also below).
The human PAI-1 gene and its 5'-flanking region were cloned in 1987 and 1988 (28) (29) (30) . The human PAI-1 gene is localised on chromosome 7, in the region q21.3-q22 (31) . It contains 9 exons and 8 introns (Figure 1 ). The transcription of the PAI-1 gene is regulated by a large number of hormones, cytokines, and growth factors. A number of transcription factor binding sites in the 5'-flanking region of the gene has been identified (for reviews, see 11, 32, 33) . The PAI-1 mRNA level is also regulated post-transcriptionally by regulation of mRNA stability (for a review, see 34). Historically, the induction of PAI-1 expression by glucocorticoid hormones is of special interest, as PAI-1 was discovered as a dexamethasoneinduced fibrinolytic inhibitor (14) .
INHIBITORY PROPERTIES OF PAI-1 AND OTHER SERPINS
By a combination of biochemical and biophysical experimental strategies, including X-ray crystal structure analysis, the major steps of the serpin inhibitory mechanism have been elucidated since the mid 80´s ( Figure  2 ). The major steps in the reaction are the following: 1, formation of a reversible Michaelis complex, in which the P 1 -P 1 ' bond in the RCL docks into the active site of the protease; 2, formation of an acyl-enzyme intermediate, in which the active site serine of the protease is attached to the hydroxyl group of the P 1 residue by an ester bond; 3, insertion of the N-terminal side of the RCL into beta-sheet A, thereby dragging the protease to the other pole of the serpin; 4, distortion of the active site of protease, preventing completion of the catalytic cycle (for reviews, see 1, 5-7).
Step 1 -The P 1 -P 1 ' bond of PAI-1 is R348(358)-M349(359). In general, the P 1 residue is the major determinant of serpin specificity (for a review, see 1), and the P 1 residue in plasminogen, the major substrate for uPA, is also an arginine. Swapping residues P 17 to P 2´ in PAI-1 with the corresponding sequence in other serpins have shown that this region plays a significant role for PAI-1 specificity (35) . The importance of the P 1 and P 1´ residues in PAI-1 have been investigated by saturation mutagenesis revealing a number of mutants that were relative specific for either uPA or tPA (36) . Additional plasminogen activator specificity has been obtained in PAI-1 variants carrying substitutions from P 3 to P 1´ (37, 38) . A series of site-directed mutagenesis studies showed that chargecharge interactions between the E-residues in the P 4 ' and P 5 ' positions of PAI-1 and basic residues in the so-called 37-loop of uPA and tPA are important for formation of the initial, reversible docking complex (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) . The importance of the P' residues of the serpin and the 37-loop of uPA and tPA for formation of the docking complex is in good agreement with the three-dimensional structures of reversible, non-covalent Michaelis complexes formed between a serpin and protease, in which the active site serine had been replaced by an alanine: Manduca sexta serpin 1B A353K with rat trypsin (50); alpha 1 -proteinase inhibitor Pittsburgh with bovine trypsin (51); heparin cofactor II with thrombin (52); antithrombin III with thrombin (53); and antithrombin III and factor Xa (54), and also the Michaelis complex formed between antithrombin III and inactive anhydrothrombin (55).
Step 2 -The docking step is followed by a locking step in which the P 1 -P 1 ' bond is being cleaved, the P 1 residue coupled to the active site serine of the protease by an ester bond. The existence of the ester bond was expected on the basis of the generally accepted theory for serine protease hydrolysis. However, its existence was directly established by the isolation of a fragment of the uPA -PAI-1 complex in which the presence of the ester bond could be unambiguously demonstrated by direct, protein chemical methods (56) .
On the basis of more detailed analyses by the use of stopped flow reaction analysis, rapid acid quench, and a fluorescent PAI-1 derivative, in which RCL insertion was prevented by pre-insertion of a peptide corresponding to the RCL into beta-sheet A, a theory for the reactions immediately before and immediately after acyl-enzyme complex formation was formulated. It is believed that the exosite bonds between the distal hinge loop of the RCL and the 37-loop of the protease retain specifically the distal part of the PAI-1 RCL in the substrate pocket, favouring reversibility of the acylation step. Acylation of the protease becomes effective only by physical separation of the products of the acylation step. This step occurs only when the initial few residues of the proximal hinge loop of the RCL insert into the top of beta-sheet A in the breach region in the position of beta-strand 4A. The process is dependent on the strictly conserved W177 (194) . Breaking of the exosite interactions are needed for the ensuing full insertion of the RCL into beta-sheet A (39, (57) (58) (59) .
Step 3 -Three-dimensional structures of the stable complex between alpha 1 -PI and trypsin (60) and between alpha 1 -PI and porcine pancreatic elastase (PPE) (61) show full insertion of the N-terminal part of the RCL as strand 4 in beta-sheet A and translocation of the protease completely to the opposite pole of the molecule. The same conclusion was reached from distance measurements by various fluorescence methods (62) (63) (64) (65) . However, recent evidence obtained by FRET-measurements on a single molecule level suggested the existence of complexes with partial insertion of the RCL (66, 67) . Whether these represent intermediates or alternative forms of stable complexes remain unclear.
Step 4 -From the fact that the protease moiety of the three-dimensional structure of the trypsin -alpha 1 -PI complex (60) was partially disordered in the crystal, it was inferred that the catalytic mechanism becomes stopped at the acyl-enzyme intermediate stage due to distortion of the Figure 2 . The inhibitory mechanism of PAI-1. On the left, the three-dimensional structure of an active PAI-1 variant with 4 mutations, introduced to delay latency transition and maintain the active state during crystallisation (120) . The following structural elements are highlighted: the surface exposed or inserted reactive center loop (red); hF (limegreen); hD and hE (dark green); gate region (orange); s1C (yellow); beta-sheet A (blue). In the middle, the Michaelis complex of a serpin and its target protease is shown, represented by the Manduca sexta serpin 1B A353K -trypsin S195A complex (50). The protease is shown in cyan. At the right, the two possible outcomes of the reaction between a serpin and a protease is shown. The upper structure illustrates the covalent complex formed, in which the protease has been moved to the opposite pole of the serpin and inactivated. The complex shown is the one between alpha 1 -PI and porcine pancreatic elastase (PPE) (61) . In some cases, the protease can complete the hydrolysis of the RCL without being inactivated, which results in the reactive center cleaved variant (lower structure at the right). The structure shown is that of cleaved PAI-1 (124) . The structures are displayed with PyMOL version 0.99rc6, DeLano Scientific LLC.
active site of the protease (6). The more recent X-ray structure of the stable complex between alpha 1 -PI and PPE also contains a distorted active site but an overall much more defined protease moiety. The protease moiety was rotated approximately 40 degrees relative to the protease moiety in the previous trypsin -alpha 1 -PI complex (61) . Thus, the extent of the serpin-induced protease-distortion remains unclear and may indeed vary between different serpin-protease pairs. Jointly, the two X-ray crystal structure analyses show that the P 1 residue of the serpin is pulled out of the protease´s S 1 pocket; that the S and the H residue of the protease active site are pulled too far apart to be efficient in catalysis; and that the protease oxyanion hole is distorted. Similar conclusions were drawn from observations of differential proteolytic susceptibility of free and serpin-complexed proteases (61, (68) (69) (70) , differential rates of reduction of disulfide linkages in free and alpha 1 -PI-complexed trypsin (71), fluorescence studies (72), and NMR studies (73). The energy needed for the distortion is believed to stem from stabilisation of the serpin in the 'relaxed' conformation by insertion of the RCL into betasheet A, as opposed to the 'stressed', relatively unstable active conformation where the RCL is exposed on the surface of the serpin (1). It is possible, however, that the serpin-trapped inactive protease exists in equilibrium with an active conformation that can complete the catalytic cycle and thereby slowly be released from a cleaved serpin (74).
However, the protease can also cleave the serpin as if it was a substrate, which renders the serpin inactive (Figure 2 ), while the protease regains full activity. Two different hypotheses have been forwarded about the two alternative pathways of the protease-serpin reaction. According to the "branched pathway" hypothesis, the covalent acyl-enzyme intermediate can go either of two paths, leading to the stable serpin-protease complex formation or to reactive centre-cleaved serpin and active protease. In this model, the rate constants for the two branches of the bifurcation can be affected by outer stimuli, such as temperature, pH, ionic strength, detergents, etc., figure 2 . B) RCL-cleaved glycosylated PAI-1 (pdb 1A7C). C) Latent, non-glycosylated PAI-1 (pdb 1LJ5). In B) and C), the RCL is coloured red; s1C is coloured yellow; the glycans at position N211 (228a) and Asn267 (278) are coloured green; and the gate-region is coloured orange.
thereby affecting the ratio of substrate-cleaved versus inhibitory serpin. In the "initial pathway" hypothesis, the serpin is believed to be in a conformation, that is destined to be either inhibitory or act as a substrate upon the encounter with the protease. Following this hypothesis, the fate of the serpin is pre-decided and not sensitive to changes in the environment of the encounter although external stimuli effecting the initial conformation of the serpin will change the outcome of the mechanism. The proposed models are not mutually exclusive (for reviews, see 3, 75).
PAI-1 LATENCY TRANSITION
Premature RCL insertion into beta-sheet A is the basis for the unique spontaneous conversion of active PAI-1 into the so-called latent state (76) , in which the Nterminal part of the intact RCL is inserted as s4A and its Cterminal extension, forming s1C in the active conformer, stretched out along the surface of the molecule (77) ( Figure  3 ). PAI-1 latency transition is one of the largest structural rearrangements known for a folded protein without a concomitant change in covalent structure, yet the sequence of conformational changes during latency transition remains largely unknown. Reported half-lives for latency transition of PAI-1 in vitro vary between 1 and 2 hours at physiological conditions, depending on protein source and experimental setup.
Several mutations in PAI-1 have been found to affect PAI-1 latency transition and are scattered throughout the molecule. Some PAI-1 variants with single mutations and modest decreases in the rate of latency transition have been obtained through heuristic protein engineering (78, 79) while others have been identified by chance (80) (81) (82) (83) . The variants with the slowest latency transition carry multiple mutations and have been obtained through in vitro molecular evolution, i.e. the creation of libraries of PAI-1 variants followed by screening (84) or selection (85) to isolate members with a slow latency transition. An interesting trait observed in the two examples of molecular evolution of PAI-1 is that the identified stabilising mutations in many cases replace the wild type PAI-1 residue with a serpin consensus residue, indicating that the instability of PAI-1 has resulted from positive evolutionary selection (84, 85) .
As the P 1 -P 1 ' bond is not cleaved during latency transition, the intact RCL must be stretched out and completely extracted from beta-sheet A to pass the socalled gate region between the loop between s3C and s4C (s3C/s4C-loop) and the loop between s3B and hG, before insertion of the RCL as s4A can be completed (77, 78, 86) (Figure 3 ). In contrast, RCL insertion during complex formation as well as during substrate behaviour implicates P 1 -P 1 ' bond cleavage (see above) so that the insertion can proceed directly. This implies that the RCL movements during the transition from stressed to relaxed PAI-1 follows different pathways. Considering that RCL insertion into beta-sheet A is several orders of magnitude faster during complex formation than during latency transition, a reasonable suggestion is that the passage of the RCL through the gate region is rate limiting for latency transition. This presumption is supported by the observation that substitutions of basic residues in the s3C/s4C-loop with acidic ones accelerate latency transition (87) . Several antibodies have been found to accelerate PAI-1 latency transition and, since the transition is an irreversible event, the effect of such antibodies cannot be explained by a stabilisation of the latent conformation. It has therefore been hypothesised that the antibodies accelerate latency transition by binding to and stabilising an intermediate, pre-latent conformation existing in an equilibrium with active PAI-1 (27, 88, 89) . By mapping the epitopes of antibodies accelerating latency transition, it has been suggested that the pre-latent form of PAI-1 is Figure 2 . B) PAI-1´s vitronectin-binding residues, as determined using the ability of vitronectin to protect PAI-1 against bis-ANS inactivation (112) , displayed on a surface presentation of PAI-1 (pdb 1OC0) having the same orientation as in A). C) The flexible joint region of active PAI-1 (pdb 1B3K) and latent PAI-1 (pdb 1LJ5). The two structures were superimposed by aligning s5A.
characterised by insertion of N-terminal residues of the RCL at the top of beta-sheet A (88-90) and partial detachment of beta-strand 1C from beta-sheet C (27) . The structure of the predicted pre-latent form could resemble that of the delta-conformation of alpha 1 -antichymotrypsin (91) . The reversible partial insertion of the N-terminal end of the RCL and extraction of s1C would enable an irreversible passage of the C-terminal end of the RCL through the gate region. The importance of the release of s1C is supported by the observation that mutations expected to weaken the interations at the s1C region facilitated the conformational transition to the latent state and affected the overall structural stability of PAI-1 (92).
PAI-1 -VITRONECTIN BINDING
Vitronectin is an M r ~78,000 extracellular glycoprotein, which is found in blood plasma in a concentration of 2-4 micromolar (93, 94) mainly in a monomeric closed conformation, and in the ECM in an open multimeric conformation (for a review, see 95). It contains, as mentioned from the N-terminus: a 44-residues long somatomedin B domain (SMB), followed by a connecting region, containing an integrin binding RGD sequence, and two hemopexin-like domains (Hp1 and Hp2), one with a heparin binding sequence. The threedimensional structure of the SMB domain has been revealed both using NMR and X-ray crystallography (96) (97) (98) . A disulphide bridge-pattern in full agreement with the reported three-dimensional structures were determined by rigorous protein chemical methods (99, 100) .
PAI-1 is present in blood and extracellular matrix in a complex with vitronectin and can bind to vitronectin in purified systems (93, (101) (102) (103) , as well as in cell culture (104) . The K d value for binding of vitronectin to active PAI-1 is in the subnanomolar range, while latent PAI-1 and other relaxed forms bind with an at least 200-fold lower affinity (105) . The high affinity binding site resides in vitronectin's N-terminal somatomedin B domain (96, 106) . Recently, it has been suggested that vitronectin may contain a second vitronectin binding site with a lower affinity (107) . The binding site for somatomedin B in PAI-1 was first suggested to reside in the flexible joint region on the basis of random mutagenesis, implicating Q125 (144) and L118 (137) (108). A later report implicated residues 116(135)-120(139) (109) . Investigations by the less accurate methods of antibody competition (110) and PAI-1 -PAI-2 chimeras (111) also gave results compatible with vitronectin binding to the flexible joint region. Analysis of the vitronectin binding surface in PAI-1 by site-directed mutagenesis is complicated by the fact that any mutation in PAI-1 observed to reduce vitronectin-binding may actually do so by increasing the fraction of relaxed PAI-1, e.g. by increasing the rate of latency transition, rather than by directly disrupting the vitronectin-binding surface. Using an alternative approach, in which the ability of vitronectin to protect active PAI-1 against an inactivating organochemical ligand was used as a basis for finding PAI-1 residues involved in PAI-1-vitronectin binding, an extensive interaction surface in PAI-1's flexible joint region was defined (Figure 4) (112) . The information obtained by that approach was later used to construct a PAI-1 variant without measurable vitronectin affinity, but normal with respect to a variety of other tested parameters, including the rate of latency transition (113) . The vitronectin interaction surface defined by these methods were in complete agreement with the X-ray crystal structure analysis of a complex between stable PAI-1 and the somatomedin B domain of vitronectin (Figure 4) (96) .
The PAI-1 binding site in the somatomedin B domain of vitronectin overlaps with binding site for the uPA receptor (uPAR) (114) (115) (116) . The binding of PAI-1 to vitronectin also competes with the binding of integrins to the adjacent RGD sequence (117, 118) .
The forms of vitronectin found in plasma and in the ECM have been shown to be very different in terms of conformation and ligand/cell binding properties. Binding of PAI-1 to vitronectin is known to cause monomeric vitronectin to multimerise into both disulphide-bridged and non-covalently multimers (119) . Multimeric vitronectin, opposed to plasma vitronectin, is able to interact with a number of molecules, which allow the protein to bind to cells and ECM (for a review, see 95). The effect of the PAI-1 -vitronectin interaction may therefore be two-fold, resulting in stabilisation but also localisation of PAI-1 activity at sites of action.
GLOBAL CONFORMATIONAL CHANGES OF PAI-1 IN ASSOCIATION WITH RCL INSERTION
When looking only at the initial and the final structures, the intramolecular rearrangements that occur during the transition from the stressed to the relaxed serpin conformation are well described by the X-ray crystal structure analyses, the only main reservation being that the structure of active PAI-1 is that of a variant with 4 mutations, introduced to delay latency transition and maintain the active state during crystallisation (120, 121) . The most prominent change is the insertion of the RCL as s4A (Figure 2 and 3) . It is clear, however, that several other structural elements are involved during the stressed-torelaxed transitions of PAI-1, and transient conformational changes during RCL insertion cannot be understood by Xray crystal structure analysis.
Insertion of the RCL as s4A involves the translocation of s1A, s2A, s3A, hF and the loop connecting hF and s3A (the hF/s3A-loop), collectively known as the small serpin fragment, relative to the rest of the molecule (the large serpin fragment) and subtle structural changes in the region around hE and hD, known as the flexible jointregion (122, 123) (Figure 2 and 4) . In the case of PAI-1, evidence for conformational flexibility of the flexible jointregion and for its differential conformation in stressed and relaxed states of PAI-1 was obtained by X-ray crystal structure analysis (77, 120, 121, 124, 125) , limited proteolysis analysis (126) , and differential binding of organochemicals (127, 128) . The structural changes following the stressed-to-relaxed transition of PAI-1 include a narrowing of a solvent-accessible hydrophobic cavity between s2A and hD. The differential vitronectinaffinity of the active, stressed form of PAI-1 on one side and of latent PAI-1 and other relaxed forms on the other and the localisation of the vitronectin binding area (see above; Figure 4 ) are in good agreement with the different conformations of the flexible joint-region in stressed and relaxed forms (77, 120, 121, 124, 125) .
On the other hand, binding of vitronectin to PAI-1 delays its rate of latency transition by a factor of 1.5 -3 fold (93, 113) . Vitronectin also decreases the k lim for loop insertion during reaction with proteases (129-131). Thus, there seems to be a bi-directional communication between the movements of the RCL and the vitronectin-binding area. How does vitronectin, when binding to the flexible joint region, affect the movements of the RCL? On the basis of biochemical studies, it has been suggested that vitronectin induces a conformational change of the RCL (132, 133) , which could be the explanation for a delayed latency transition due to an impeded passage through the gate region, a stabilisation of beta-sheet C, or a slower rate of RCL insertion. On the basis of the three-dimensional structure of the PAI-1 -somatomedin B complex, Zhou et al. (2003) suggested that vitronectin simply sterically hinders the shift of beta-strands 2A and 3A towards hE and thus delays the necessary opening of beta-sheet A. However, certain observations concerning K325(335)A in beta-strands 5A argues against this mechanism. Residue K325(335), which is well conserved in the serpin family (4) appears to form an important link between the small and the large serpin fragment. It is situated above the shutter region with its side chain pointing towards the hF/s3A-loop. In PAI-1, the side chain of K325(335) was suggested to interact with the small serpin fragment via a hydrogen bond to the backbone of the hF/s3A-loop (134) or via a chloride ion coordinated between two lysine residues in s5A (K325(335) and K327(337)) and two backbone amides from the hF/s3A-loop (125) . In alpha 1 -PI, hydrophobic interactions between K325(335) and residues in the hF/s3A-loop were suggested (135) . Substitutions of K325(335) with small hydrophobic amino acids, e.g. alanine, led to increased thermal stability and substrate behaviour of alpha 1 -PI, suggesting that burial of the side chain of K325(335) between beta-sheet A and the hF/s3A-loop contributes to the metastability of the stressed conformation (135, 136) . Substitution of K325(335) in PAI-1 with alanine delays latency transition, which could be interpreted as an increased stability of the stressed conformation (137) . In addition, several observations suggested that K325(335) in PAI-1 is involved in the communications that take place within active PAI-1 as a response to vitronectin and certain monoclonal antibodies (for a review, see 7). For example, whereas the K325(335)A substitution delayed latency transition in the absence of vitronectin, it accelerated latency transition in the presence of vitronectin (137) . It is the latter observation, which is difficult to reconcile with vitronectin simply forming a physical barrier to expansion of betasheet A. It rather argues that the effect of vitronectin is a conformational one.
During beta-sheet A opening and RCL insertion, s3A and s5A must slide apart in a shutter-like movement over the underlying hB (122) . The central part of s3A and s5A and the N-terminal part of hB are therefore referred to as the shutter region (2). The shutter region contains a buried cluster of residues with a complicated hydrogen bonding network, involving the amino acids in positions 53(69) and 56(72) in hB, 186 (203) in s3A, and 334(344) in s5A (1), but differently organised in the stressed and the relaxed conformations (138) . Also, the clustering of naturally occurring, disease-causing mutations in the shutter region of various serpins other than PAI-1 highlights the importance of the integrity of its hydrogenbonding network for the normal orientation of the RCL, most of the mutations appearing to cause loop-sheet polymerisation (139-145). Although PAI-1 has an unusual amino acid composition in these positions, the less well resolved X-ray crystal structures of the various forms of PAI-1 are compatible with a similar network in this serpin (77, 120, 121, 124, 125) . A number of substitutions in positions 53(69), 56(72) and 334(344) in PAI-1 strongly accelerated latency transition (134) , while the substitutions P54(70)S and P54(70)T delayed latency transition (84) . Thus, the amino acid composition of the shutter region of PAI-1 affects the rate of latency transition, either by affecting beta-sheet A opening, the release of s1C, the rate of passage of the RCL through the gate region, or by further destabilising the stressed conformation of PAI-1.
In its translocation away from s5A during RCL insertion, other secondary structural elements in the small serpin fragment change position relative to each other. Based on an analysis of the three-dimensional structures of native and P 1 -P 1 ' cleaved alpha 1 -PI, Whisstock et al. (2000) concluded that hF changes its packing relative to beta-sheet A during RCL insertion with part of the hF/s3A-loop as a flexible hinge for this rearrangement (123) . With PAI-1, a variety of observations have implicated movements of the elements of the small serpin fragment during latency transition as well as complex formation. Significant effects on the rate of latency transition were observed by substitutions of residues involved in interactions connecting different secondary structural elements, including residues in hF, the hF/s3A-loop, and s1A (82, 84, 85, 120, 121, 125) . Intriguingly, the significant acceleration of latency transition of PAI-1 conferred by certain point mutations in s1A or hF was counteracted by vitronectin (82) , implying that the latency transition-delaying effect of vitronectin might also involve conformational changes of s1A and hF. Some point mutations in s1A and hF also increased the tendency to substrate behaviour (82, 146) . Furthermore, antibodies with epitopes encompassing hF and the hF/s3A-loop can induce substrate behaviour (147, 148) , presumably by inducing a rigidity in the small serpin fragment which is not compatible with a rate of strand insertion fast enough for normal complex formation (148) . The observation that the substrate behaviour induced by one of these antibodies is strongly potentiated by vitronectin also points towards regulation of the flexibility of this region by vitronectin (129-131, 148, 149 ). On the basis of separate substitutions of all residues in hF with alanine, concluded that interactions of hF and its neighbouring structural elements regulate the rate of latency transition (146) . Gettins (2002) proposed that serpins´ alpha-helix F must be temporally displaced towards alpha-helix E to make space for the protease as it translocates from its position in the Michaelis complex to its position in the stable complex (75).
PAI-1 POLYMERISATION
Serpin polymerisation can be induced by specific mutations and underlies several inherited diseases, "serpinopathies" (for a review, see 150). Serpins may polymerise by the RCL of one molecule forming an additional strand in beta-sheet A or beta-sheet C of another molecule (for a review, see 2). PAI-1 has been shown to be able to polymerise in vitro. In vitro, the plasminogen activator inhibitory activity of PAI-1 can be neutralised by a number of structurally diverse organochemical compounds with IC 50 values in the micromolar range (for a review, see 9). Mutational studies and fluorimetric binding analysis indicated that some of these compounds bind to a hydrophobic cavity in the flexible joint-region (127, 128) . Activity neutralisation proceeded through two consecutive steps, the first one consisting in conversion to a form displaying substrate behaviour, the second one consisting in conversion to forms inert to plasminogen activators. The second step was associated with polymerisation of PAI-1 (128, 151) . As investigated by native gel electrophoresis, the size of the PAI-1 polymers ranged from dimers to multimers of more than 20 units (152) . During incubations with urokinase-type plasminogen activator, the polymers were slowly converted to reactive centre-cleaved monomers, indicating substrate behaviour of the terminal PAI-1 molecules in the polymers. Interestingly, PAI-1 could form co-polymers with the other serpin heparin cofactor II. On the basis of these results, it was suggested that the binding of ligands in a specific region of PAI-1 leads to insertion of the RCL of one molecule into the upper part of the cleft between s3A and s5A of another molecule. Induction of polymerisation by small organochemical ligands have not been observed with other serpins (152) . PAI-1 has also been reported to polymerise at pH 4, but since both latent and active PAI-1 polymerised under these acidic conditions (153) , the underlying molecular mechanism must differ from that induced by PAI-1-neutralisers. It is not known whether PAI-1 polymerisation is of physiological relevance.
BIOCHEMICAL IMPORTANCE OF PAI-1 GLYCOSYLATION
With few exceptions, all biochemical studies on PAI-1 have been performed with PAI-1 expressed in E. coli. Because of the short culture time needed to achieve a high level of expression, PAI-1 expressed in E. coli remains in the active form, in contrast to PAI-1 expressed naturally or recombinantly by mammalian cells, which must be reactivated after purification from conditioned culture medium collected after culturing cells for several days, during which time the secreted PAI-1 is converted to the latent form. However, PAI-1 expressed in E. coli lacks glycosylation. While the basic serpin inhibitory mechanism from all available evidence does not depend on the glycosylation, the binding and effect of certain artificial ligands have been shown to differ between glycosylated and non-glycosylated PAI-1. This was true for the binding of PAI-1 by 4 activity-neutralising monoclonal antibodies. For example, MAI-12 had a more than 10 fold higher affinity to glycosylated PAI-1 than to non-glycosylated PAI-1. Expression in mammalian cells of PAI-1 variants, in which one or the other of the utilised glycosylation sites was mutationally inactivated, showed that the higher affinity of MAI-12 to glycosylated PAI-1 depended on glycosylation at N267 (278) (25) . Results like these stress the importance of the expression system used when developing and studying the mechanism of action of PAI-1 inactivating compounds of potential clinical importance. However, it remains unknown whether glycosylation variants of PAI-1 exist in vivo. PAI-1  COMPLEXES  TO  ENDOCYTOSIS  RECEPTORS  OF  THE  LOW  DENSITY 
BINDING OF PLASMINOGEN ACTIVATOR -

LIPOPROTEIN RECEPTOR FAMILY
The low density lipoprotein receptor (LDLR) family of endocytosis receptors includes a number of receptors composed from the same type of domains, but with variable sequence and variable number of each type of domain. The known mammalian members of the family are, besides LDLR itself, low density lipoprotein receptorrelated protein-1A (LRP-1A), LRP-1B, megalin or LRP-2, very low density lipoprotein receptor (VLDLR), and apolipoprotein receptor 2 (apoER2) (Figure 5 ). The domains include complement-type repeats (CTRs), YWTD repeats, and epidermal growth factor precursor domains. All the receptors have a transmembrane alpha-helix and a cytoplasmic C-terminal domain with one or more sequences mediating endocytosis via clathrin-coated pits (for a review, see 154-157). The classical ligands for LDLR are apolipoproteins B100 and E (155), and these apolipoproteins are also ligands to the other receptors. In 1990, however, it was discovered that receptors of the family also have non-apolipoprotein ligands, as the receptor for protease-complexed alpha 2 -macroglobulin was found to be identical to LRP-1A (158, 159) , the amino acid sequence of which had been reported two years earlier (160) .
Also in 1990, it was reported that uPAR-bound uPA -PAI-1 complex is endocytosed efficiently, at least by some cell types (161) (162) (163) . However, the molecular mechanism behind this phenomenon remained unknown until 1992, when it was reported that tPA -PAI-1 complex (164) and uPA -PAI-1 complex (165) can bind to and be endocytosed by LRP-1A. Slightly later, it was realised that LRP-1A can function as a clearance receptor for tPA (164, 166, 167) . However, the free proteases and free PAI-1 are endocytosed much slower than their complexes by these receptors (164, 165, 168) . The differential endocytosis rate of free proteases and free PAI-1 on one side and their complexes on the other is reflected in a differential affinity of the complexes and the free components to the receptors in vitro: uPA -PAI-1 complex binds to LRP-1A with an affinity which is approximately 100-fold higher than that of free uPA, active PAI-1, latent PAI-1 and cleaved PAI-1 (K d of 0.5 and 50 nM, respectively) (168). Later, it was shown that also megalin (169, 170) , VLDLR (171, 172) , and LRP-1B (173, 174) bind and mediate endocytosis of plasminogen activator -PAI-1 complexes. Besides, sorting protein-related receptor (sorLA; LR11), a receptor related to the LDLR family by containing a cluster of 11 CTRs, but also other types of domains, and having a ligand repertoire overlapping with that of LDLR family, also binds plasminogen activator -PAI-1 complexes (175).
The binding of the complexes to these receptors may function in the clearance of the complexes both locally in the tissues and systemically in the liver, which has an abundant expression of LRP-1A. In spite of the low affinity of free uPA, tPA or PAI-1 to these receptors, the receptors may still be important for clearance of the free components, as a high receptor density may compensate for a low affinity. Certainly, LRP-1A is able to mediate endocytosis and degradation of tPA (164, 166, 167) , also in vivo (176) . But locally, on cell surfaces, the different endocytosis rate of uPA and uPA -PAI-1, respectively, is functionally important. Another important aspect is that uPAR-bound uPA -PAI-1 complex is endocytosed and degraded much faster than uPA -PAI-1 complex free in the fluid phase, presumably because endocytosis mediated by the relatively low affinity binding to the endocytosis receptors (K d around 500 pM) is facilitated by accumulation of complex on the cell surface by the relatively high affinity binding to uPAR (K d around 50 pM) (165, 168, 177) . uPAR is, as a consequence of its binding to the uPA moiety of the uPA -PAI-1 -endocytosis receptor complex, co-endocytosed (178) , and later recirculated to the cell surface (179) .
Since the early 90es, evidence has been accumulating that each of these receptors mediate endocytosis of many structurally unrelated ligands. For instance, the receptors bind matrix metalloproteases, extracellular matrix proteins, and viruses. The binding specificities of individual receptors are overlapping, but still distinct. A ligand of special interest is the M r ~40,000 receptorassociated protein (RAP), first identified because it co-purifies with LRP-1A (159) and later found to be an endoplasmic reticulum-localised chaperone, ensuring correct folding of receptors from the LDLR family (for reviews, see [180] [181] [182] . RAP consists of 3 homologous domains (183) (184) (185) (186) .
Moreover, some receptors of the LDLR family may also have a signalling function (for reviews, see 154, 156, 187), and binding of uPA -PAI-1 complex to VLDLR has also been reported to initiate an intracellular signal transduction cascade (188) . In this connection, it is of interest to note that among the endocytosis receptors binding the uPA -PAI-1 complex, endocytosis occurs at very diverse rates: LRP fast, VLDLR moderate, LRP-1B and sorLA slow (174, 175, 189) . The slowly endocytosing receptors seem to be most relevant when considering a potential signaling function.
Most interesting in the present context, these receptors' ligands include many serine proteases, serpins, and their complexes (uPA -PN-1, uPA -PCI, uPA -C1 inhibitor, tPA -PAI-1, tPA, pro-uPA, PAI-1, neutrophil elastase -alpha 1 -PI, trypsin -alpha 1 -PI, C1 inhibitor -C1s, thrombin -antithrombin III, thrombin -heparin cofactor II, thrombin -PCI, thrombin -PN-1, factor IXa, cathepsin Galpha 1 -antichymotrypsin). Many, although not all, bind with a subnanomolar K d (for reviews, see 154, 155, 157, 187) . The uPA -PN-1 complex appears to represent a special case as far as the binding to LRP and VLDLR is concerned. The uPA -PN-1 complex binds as well to LRP as uPA -PAI-1, and appears to have a particularly high affinity to VLDLR, 5-15 fold higher than that of uPA -PAI-1 complex to VLDLR (190) and is the only proteaseserpin complex known to be able to compete the binding of RAP (191) .
Because of the high-affinity binding of so many structurally unrelated ligands by these receptors, understanding the biochemistry of this type of receptorligand interaction is a special challenge. A specific challenge in the case of plasminogen activator -PAI-1 complexes is understanding the biochemistry of the different binding affinity of each component separately and of the complex, being related to the inhibitory mechanism of serpins. What is the biochemical mechanism behind the increased affinity of the complex? A priory, several possibilities could be contemplated, including 1, an increased affinity associated with a conformational change of PAI-1 following complex formation; 2, an increased affinity associated with a conformational change of the protease; 3, an increased affinity associated with conformational changes of both components; 4, an avidity effect due to the combination of two binding sites on the same ligand, one from uPA and one from PAI-1. There is no X-ray crystal structure analysis of any complex between an endocytosis receptor and a serine protease, a serpin, or their complex. But some inferences can be made from the crystal structures of the third domain of RAP in complex with a CTR pair from LDLR and of human rhinovirus serotype 2 in complex with CTRs from VLDLR (192, 193) . Also of relevance is an X-ray structure analysis of LDLR crystals obtained at pH 5, in which the beta-propeller bends back and makes contact with the CTR cluster in a way believed to mimic ligand binding (194) . Moreover, a model of a complex between a pair of CTR repeats and RAP domain 1, based on their separate NMR structures, were published recently (195) . Common to all of these structures is the fact that binding to the CTRs is mediated through basic and hydrophobic residues in the ligand. Also, the three-dimensional structures of several CTR repeats from LDLR and LRP have been determined (196) (197) (198) (199) (200) (201) (202) (203) .
But so far, the only available direct knowledge about contacts between plasminogen activator -PAI-1 complexes and the endocytosis receptors has been obtained by site-directed mutagenesis and the use of deletion variants of uPA. The initial search for receptor-binding residues in serpins focused on the flexible joint region, because the flexible joint region is known to change conformation upon RCL insertion and because it is not covered by the protease in the complex. Also, the initial search concentrated on basic residues, as heparin was known to inhibit the binding of several ligands to receptors of the LDLR family (for a review, see 204). Binding of uPA -PAI-1 complex to LRP and VLDLR requires basic residues in hD and hE in the flexible joint-region in the inhibitor. The implicated residues were R78(97), K82(101), R120(139), and K124 (143) The observation that complexes of the same serpin with different proteases have different affinities to LRP and VLDLR (190) suggests that contacts between protease and receptor as well as between PAI-1 and receptor contribute to the increased affinity, but the contribution may come from the A-chains as well as from Figure 6 . The receptor binding surface in the uPA -PAI-1 complex. The uPA -PAI-1 complex shown is a model constructed from the structure of the α 1 -PI in complex with PPE 61 (pdb file 2D26), by aligning the alpha 1 -PI part of that structure with the structure of the cleaved PAI-1 (pdb file 9PAI) and the PPE part of the structure with that of uPA (pdb file 1F92). Thus, the orientation of the uPA -PAI-1 complex is realistic but it does not allow any predictions of exact distances between amino-acid residues. A) The uPA -PAI-1 complex with the different structures coloured in the same way as in Figure 2 . uPA is coloured cyan. B) Surface presentation of the uPA -PAI-1 complex shown in the same orientation as in A. PAI-1 is coloured grey and uPA cyan. Residues important for binding to VLDLR are coloured red in both structure. PAI-1 numbering is according to (18) . uPA numbering is according to (231) with the chymotrypsin template numbering in parenthesis.
the serine protease domain. In fact, the 10-fold difference in affinity between the complexes of PAI-1 with full length uPA and LMW-uPA, lacking almost the entire A-chain (168, 207, 208) proves the involvement of the A-chain in the binding to the endocytosis receptors. Deletion of the Nterminal growth factor domain of uPA alone reduced the affinity 2-4-fold, indicating that both the growth factor domain and the kringle contributes to receptor binding (208) . Stefansson et al. (207) supported a theory of lack of importance of the serine protease domain by their report of equal receptor-binding affinities of PAI-1 in complex with the serine protease domain of uPA and with trypsin, respectively. However, a more detailed analysis showed that substitution of a cluster of basic residues near the 37-loop and 60-loop of uPA reduced the receptor-binding affinity of the uPA -PAI-1 complex approximately twofold. The localization of the implicated residues in the three-dimensional structures of uPA and PAI-1 shows that they form a continuous receptor-binding area spanning the serpin as well as the A-chain and the serine protease domain of uPA. Thus, the 10-100 fold higher affinity of the uPA -PAI-1 complex compared with the free component seems to depend on the bonus effect of bringing the binding areas on uPA and PAI-1 together on the same binding entity. Whether or not conformational changes of the protease domain or the serpin upon complex formation also contribute to the increased affinity can probably best be decided on the basis of X-ray crystal structural analysis.
Ligand binding by receptors of the LDLR family is critically dependent on the CTR clusters ( Figure 5) . LDLR, VLDLR, apoER2, and sorLA have only one such cluster, with 7 (LDLR), 8 (VLDLR, apoER2), or 11 (sorLA) CTRs, respectively. LRP-1A has 4 clusters, of 2, 8, Figure 7 . uPA -PAI-1 binding site of LRP. Top panel, the amino acid sequence of the 8 CTRs of the 2nd cluster in LRP. CTR5 and CTR6, the pair of which has the highest affinity to uPA -PAI-1, are shown in white. Residues implicated in the binding are highlighted. Bottom panel, the three-dimensional structure of CTR3 from LRP (200) , in a ribbon presentation (left) and surface presentation (right). Indicated are W22 and D27, which were implicated in uPA -PAI-1 binding. In both panels, the numbering of the amino acids in the CTRs are according to (198) .
10, and 11 CTRs, respectively (for a review, see 155). LRP CTR clusters II and IV have been shown to bind uPA -PAI-1 complex (209) (210) (211) (212) . LRP-1B has 4 clusters, of 2, 8, 10, and 12 CTRs, respectively, and CTR clusters II and IV have been shown to bind plasminogen activator -PAI-1 complexes (173) . Megalin has 4 clusters, of 7, 8, 10, and 11 CTRs and the second cluster has been implicated in ligand binding (213) . As originally concluded for LDLR itself (214, 215) , the ligand-receptor binding specificity seems to depend on each individual ligand making contacts to a specific set of CTRs in each receptor, and this also appears to be true in the case of plasminogen activator -PAI-1 complexes. By expression of VLDLR variants lacking specific complement-type repeats, it was found that the second CTR in the cluster of 8 in this receptor was required for maximal affinity to uPA -PAI-1 complex (216) . Reportedly, tPA -PAI-1 complex, PAI-1, and pro-uPA can bind to a fragment encompassing CTR3-CTR4-CTR5-CTR6-CTR7 (the CTRs of the N-terminal CTR-cluster 1 being numbered as number 1 and 2) of CTR cluster II of LRP (211, 217, 218) . Andersen et al. (2001) showed that the minimal functional unit capable of mimicking the binding of uPA -PAI-1 complex to LRP CTR cluster II is a 2-CTR fragment, and that the CTR5-CTR6 pair had the highest affinity to the uPA -PAI-1 complex (219). The substitutions W22S and D27N (using the numbering of (198) in either CTR5 or CTR6 resulted in a reduced binding of uPA -PAI-1, whereas substitutions of two different R residues had no effect on the binding. The substitution D28N in CTR5 also resulted in a reduced binding. W22 and D27 are centrally placed in the threedimensional structure of the CTRs, as indicated on the three-dimensional structure of LRP CTR3 (Figure 7) . Whereas W22 and D27 are important for the binding of uPA -PAI-1 complex, the observations with these 2 residues do not directly or totally explain the specificity underlying the specific binding of uPA -PAI-1 complex to CTR5-CTR6, as the W22 and D27 are also found in CTR3, CTR4, CTR7, CTR8, and CTR9. The D28 residue may contribute to the specificity, as it is only found in CTR5. Among the CTRs of LRP CTR cluster II, this residue is only found in CTR5 and could for that reason be assumed to be implicated in conferring specificity to the binding, but then again, none of the CTRs in VLDLR has the combination W22, D27, D28.
From the dimensions of the CTRs emerging from the X-ray crystal structure analysis of LDLR (194) , the uPA-serine protease domain and the PAI-1 moieties could each make contact to a CTR. The A-chain of uPA would bind to a third CTR. Thus, whereas the individual components uPA and PAI-1 would only be able to make contact to one or two CTRs, the complex would be able to make contact to three CTRs and thus bind with a high affinity.
CONCLUSIONS AND PERSPECTIVES
Studies of PAI-1 and other serpins in the latest two decades have shown that their distinguishing feature is the conversion from the metastable native, "stressed" conformation to the loop-inserted, "relaxed" conformation. This conformational change forms the basis for their inhibitory mechanism. RCL insertion is coupled to both transient and permanent global conformational changes. Thus, during the insertion of the RCL, the shift of the small serpin fragment, and the conformational change of the flexible joint region in connection with both complex formation and latency transition, there are concerted conformational changes of the shutter region and the surrounding part of s5A, and the small serpin fragment. On the other side, binding of vitronectin to the small serpin fragment of PAI-1 may affect the movements of the RCL. The elucidation of serpin inhibitory mechanism and serpin conformational changes has thus contributed to the general understanding of protein conformational changes and of enzymes catalytic and inhibitory mechanisms.
PAI-1 is a potential therapeutic target in cardiovascular diseases as well as in cancer (for a review, see 9, 12, 220-222). The detailed knowledge about the molecular interactions of PAI-1, as reviewed here, has laid a solid foundation for the development of PAI-1 inactivating compounds, be they organochemicals, monoclonal antibodies, or peptides (for a review, see 10, 12) . Such inactivating agents may be used both for target validation in animal disease models and leads in drug development.
In spite of the substantial progress, many challenges of a basic protein chemical nature still lie ahead. Thus, the early steps of the protease -serpin interaction still contain considerable elements of "standard mechanism inhibition" characteristic for inhibitors of the Kunitz, Kazal and other families, in which an exposed loop also inserts into the active site, but in which there are no ensuing global conformational change of the inhibitor (for a review, see 223) . The importance of exosite interactions for the progression from standard mechanism inhibition to the RCL insertion-based mechanism is of considerable interest. The latency transition is one of the largest structural rearrangements known for a folded protein without a concomitant change in covalent structure. Yet, the sequence of conformational changes during latency transition remains largely unknown. It is a challenge to understand the conformational changes induced into PAI-1 by its natural ligand vitronectin and the many organochemicals, monoclonal antibodies, and peptides, which have been developed in order to be able to inactivate PAI-1 in vivo. Finally, a structural characterisation of the binding of protease -PAI-1 complexes to the endocytosis receptors would be an important step.
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